GSK Oral Carbapenem FDA Approval Surprise

GSK and partner Spero Therapeutics received FDA approval for the first-ever oral carbapenem antibiotic for complicated urinary tract infections — a genuine 'first-in-class' designation in a category that has been limited to IV-only administration for decades. This is a significant commercial and scientific milestone; oral carbapenems address a critical unmet need in antimicrobial resistance, and the approval opens a sizable outpatient market previously inaccessible to this drug class. For Spero, a small-cap biotech, this transforms its commercial profile and likely triggers milestone payments and royalties; for GSK, it adds a differentiated antibiotic franchise. Spero shares should re-rate sharply on the news, with potential M&A interest from larger pharma given the validated asset.